What are the defining events for multiple myeloma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Multiple Myeloma Defining Events (SLiM-CRAB Criteria)

Multiple myeloma is diagnosed when there is ≥10% clonal bone marrow plasma cells or biopsy-proven plasmacytoma PLUS at least one myeloma-defining event from either CRAB features or SLiM biomarkers. 1

CRAB Features (End-Organ Damage)

These represent symptomatic disease requiring treatment:

  • C (Calcium): Serum calcium >11 mg/dL (>2.75 mmol/L) 1
  • R (Renal): Creatinine >2 mg/dL OR creatinine clearance <40 mL/min 1, 2
  • A (Anemia): Hemoglobin <10 g/dL OR >2 g/dL below normal 1, 2
  • B (Bone): One or more osteolytic lesions on skeletal radiography, whole-body MRI, or whole-body FDG-PET/CT 1, 2

SLiM Biomarkers (High-Risk Features)

These biomarkers predict near-inevitable progression to symptomatic disease and warrant treatment initiation before end-organ damage occurs: 1, 3

  • S (Sixty): ≥60% clonal plasma cells in bone marrow 1, 2
  • Li (Light chain ratio): Involved/uninvolved serum free light chain ratio ≥100 (with involved FLC ≥100 mg/L) 1, 2
    • Critical caveat: Recent data suggests patients with FLC ratio >100 but urinary monoclonal protein <200 mg/24h have only 13.5% risk of symptomatic progression at 2 years, with median time to progression of 7.9 years 4. Exercise caution in this subgroup.
  • M (MRI): >1 focal marrow lesion on MRI (each ≥5 mm in size, nonosteolytic) 1, 2

Key Algorithmic Points

The updated 2014 IMWG criteria fundamentally changed MM diagnosis by incorporating SLiM biomarkers alongside traditional CRAB features. 3 This allows treatment initiation before irreversible organ damage occurs in high-risk patients.

All myeloma-defining events together are termed "SLiM-CRAB." 1, 2 Patients meeting any single criterion from either category have active multiple myeloma and should be offered treatment.

Distinguishing from Smoldering Myeloma

Smoldering (asymptomatic) MM is defined as:

  • Serum M-protein (IgG or IgA) ≥30 g/L AND/OR
  • Clonal bone marrow plasma cells 10-59% AND
  • Absence of any CRAB features, SLiM biomarkers, or amyloidosis 1, 2

Imaging Clarifications

The IMWG clarified that bone disease can be diagnosed by skeletal radiography, whole-body MRI, or whole-body FDG-PET/CT—not just conventional X-rays. 1, 5 This increases sensitivity for detecting bone involvement and allows earlier diagnosis.

Common Pitfalls

  1. Don't wait for CRAB features in patients with SLiM biomarkers—these patients have active MM requiring treatment 1, 3
  2. For FLC ratio ≥100: Verify involved FLC is ≥100 mg/L AND check 24-hour urine protein; if <200 mg/24h, progression may be slower than expected 4, 6
  3. MRI focal lesions must be ≥5 mm to qualify as myeloma-defining 5, 7
  4. Bone marrow plasma cells ≥60% alone may transform more slowly than previously thought in absence of other high-risk features 4

Related Questions

Should all four CRAB criteria (hypercalcemia, renal insufficiency, anemia, bone lesions) be required for the diagnosis of active multiple myeloma?
In a patient about to start bortezomib‑lenalidomide‑dexamethasone therapy for multiple myeloma with TSH 6.5 mIU/L and normal free T4, should levothyroxine be initiated now?
What diagnostic work‑up and initial treatment should be undertaken for a patient with a high likelihood of multiple myeloma and a serum free light chain (lambda) level of 114?
What are the guideline‑recommended diagnostic work‑up and management strategies for multiple myeloma, including initial evaluation, risk‑adapted therapy, maintenance, supportive care, and relapse treatment?
What are the CRAB (Hypercalcemia, Renal failure, Anemia, Bone lesions) criteria for multiple myeloma?
In a patient receiving methadone linctus (syrup) who develops a persistent cough, how should the cough be evaluated and managed?
What is the appropriate evaluation and management for a patient presenting with pelvic pain and a burning sensation?
Should a patient with newly diagnosed diabetes begin treatment now instead of waiting for his appointment in two weeks?
What are the recommended propofol doses for induction and maintenance in adults (including elderly or reduced cardiac output), pediatric patients ≥3 months, and for procedural sedation?
What are the treatment options for trigger finger of the thumb?
How should a 13-month-old male with a rash after receiving influenza, pneumococcal conjugate (PCV‑20) and varicella vaccines be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.